Assetmark Inc. Boosts Stock Position in Doximity, Inc. (NASDAQ:DOCS)

Assetmark Inc. grew its position in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 31,906.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,562 shares of the company's stock after purchasing an additional 10,529 shares during the quarter. Assetmark Inc.'s holdings in Doximity were worth $564,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of DOCS. Global Retirement Partners LLC boosted its holdings in Doximity by 468.1% during the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock valued at $29,000 after acquiring an additional 440 shares during the period. UMB Bank n.a. increased its stake in shares of Doximity by 69.1% in the fourth quarter. UMB Bank n.a. now owns 575 shares of the company's stock worth $31,000 after buying an additional 235 shares during the period. Farther Finance Advisors LLC boosted its position in Doximity by 324.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 789 shares of the company's stock valued at $34,000 after buying an additional 603 shares during the period. Morse Asset Management Inc bought a new stake in Doximity in the 3rd quarter worth $46,000. Finally, IFP Advisors Inc increased its position in shares of Doximity by 344.1% in the fourth quarter. IFP Advisors Inc now owns 1,328 shares of the company's stock valued at $71,000 after acquiring an additional 1,029 shares during the period. 87.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DOCS has been the topic of several recent analyst reports. Raymond James reissued an "outperform" rating and issued a $83.00 target price (up from $65.00) on shares of Doximity in a research note on Friday, February 7th. Mizuho boosted their target price on Doximity from $55.00 to $65.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Leerink Partnrs upgraded Doximity from a "hold" rating to a "strong-buy" rating in a report on Friday, February 7th. Piper Sandler upgraded shares of Doximity from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $31.00 to $78.00 in a report on Friday, February 7th. Finally, The Goldman Sachs Group upped their price objective on shares of Doximity from $58.00 to $80.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $64.22.

Remove Ads

Insider Activity at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company's stock, valued at approximately $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 37.40% of the stock is owned by corporate insiders.

Doximity Trading Down 5.4 %

NASDAQ:DOCS traded down $3.50 on Thursday, reaching $60.81. 1,970,742 shares of the stock traded hands, compared to its average volume of 2,430,474. The company has a market capitalization of $11.35 billion, a price-to-earnings ratio of 60.81, a PEG ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $85.21. The company's fifty day simple moving average is $63.47 and its 200 day simple moving average is $52.31.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.